Hassan MS, Jawad AM. Assessment of Pathological Response to Neoadjuvant Therapy: Comparison Between Pertuzumab-Based and Non-Pertuzumab Protocols in HER2-Positive Breast Cancer. MECOJ [Internet]. 2026 Jul. 12 [cited 2026 Nov. 9];2(3):1-9. Available from: https://scientificsteps-group.com/ojs/ojs3/index.php/mecoj/article/view/229